MAPT and Mental deterioration: This work applies a novel temporal modelling approach to amyloid PET and plasma p-tau217 data from two different assay platforms to characterize when plasma p-tau217 become abnormal relative to amyloid PET, tau PET, and cognitive decline in a predominantly cognitively unimpaired cohort.